Phibro Animal Health Corporation

Phibro Animal Health Corporation (PAHC) Market Cap

Phibro Animal Health Corporation has a market capitalization of $2.19B.

Financials based on reported quarter end 2025-12-31

Price: $54.09

-2.42 (-4.28%)

Market Cap: 2.19B

NASDAQ · time unavailable

CEO: Jack Clifford Bendheim

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

IPO Date: 2014-04-11

Website: https://www.pahc.com

Phibro Animal Health Corporation (PAHC) - Company Information

Market Cap: 2.19B · Sector: Healthcare

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.

Analyst Sentiment

55%
Buy

Based on 13 ratings

Analyst 1Y Forecast: $36.33

Average target (based on 2 sources)

Consensus Price Target

Low

$49

Median

$49

High

$49

Average

$49

Downside: -9.4%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PHIBRO ANIMAL HEALTH CORP CLASS A (PAHC) — Investment Overview

🧩 Business Model Overview

Phibro Animal Health Corporation (PAHC) is a diversified animal health and mineral nutrition company with a global footprint. The company specializes in developing, manufacturing, and marketing a broad range of products for food and companion animals. Phibro’s business model is built on serving the livestock and animal protein industries with essential products needed for animal health, productivity, and welfare. The company’s portfolio spans a substantial suite of pharmaceuticals—including medicated feed additives, nutritional specialty products, and vaccines—supplemented by mineral nutrition solutions. These offerings help improve animal health, support sustainable protein production, reduce disease incidence, and ultimately enable producers to operate more efficiently in dynamic meat, dairy, poultry, and aquaculture sectors worldwide. With direct relationships spanning large integrated producers to regional distributors and veterinarians, PAHC actively invests in research and international expansion to broaden its addressable end markets.

💰 Revenue Streams & Monetisation Model

Phibro generates revenue primarily via the direct sale of animal health products, vaccines, mineral nutrition products, and performance-enhancing nutritional solutions to agricultural producers, distributors, feed manufacturers, and veterinarians. The company segments its operations into three key verticals: - **Animal Health (core segment):** This segment includes medicated feed additives (MFAs), nutritional specialty products, and vaccines for poultry, swine, cattle, aquaculture, and companion animals. Medicated feed additives and nutritional specialties address both preventative and therapeutic needs across a variety of global livestock markets. - **Mineral Nutrition:** PAHC offers essential minerals and customized blends to livestock producers, targeting overall animal growth and productivity; this area provides a steady, lower-margin, but less cyclical revenue stream. - **Performance Products:** This smaller division covers industrial chemicals, including specialty products used in the personal care, industrial, and chemical processing sectors. Recurring revenue arises from the sale of consumable animal health products and feed additives, reflecting ongoing livestock production cycles. Many products are integral to customers’ herd/flock management, often leading to longstanding accounts and predictable demand curves.

🧠 Competitive Advantages & Market Positioning

Phibro occupies a differentiated niche within the broader agribusiness and animal health industries. The company leverages several competitive advantages: - **Diverse Product Portfolio:** PAHC provides a comprehensive suite of solutions across species (poultry, swine, cattle, aquaculture, and companion animals), reducing revenue dependence on any one submarket or geography. - **Regulatory Expertise:** The company benefits from established relationships with regulatory agencies and a deep track record of navigating complex global registration and compliance processes, which serves as a significant barrier to entry for new entrants and smaller competitors. - **Strong Distribution Networks:** Through long-standing relationships with integrators, feed millers, veterinarians, and independent producers, Phibro maintains robust channels that foster customer loyalty and recurring sales. - **Research and Development:** Ongoing investment in R&D has enabled the company to periodically refresh its product pipeline with updated formulations, innovative vaccines, and natural/nutritional alternatives, addressing both evolving disease challenges and shifting regulatory landscapes. - **Global Presence with Emerging Market Focus:** The company has established operations and partnerships internationally, especially in Latin America, Asia, and other regions where protein consumption is rising and livestock production is modernizing.

🚀 Multi-Year Growth Drivers

Phibro’s future prospects are tied to several secular and industry-specific growth drivers: - **Rising Global Protein Demand:** Increasing urbanization, disposable incomes, and population growth—particularly in emerging markets—support secular demand for animal protein, boosting the need for animal health solutions. - **Shift to Preventative Health and Nutrition:** Producers are increasingly focused on productivity, animal welfare, and preventive care, seeking alternatives to antibiotics (in line with regulatory and consumer preferences) such as vaccines and specialty feed additives. - **Expanding International Footprint:** Expansion into developing markets leverages long-term dietary changes and the modernizing of animal husbandry practices, offering new customer acquisition potential. - **Innovation in Disease Management:** New products addressing major viral, bacterial, and parasitic diseases can provide incremental revenue streams, particularly as global biosecurity awareness rises. - **Regulation and Disease Outbreak Responses:** Heightened industry vigilance regarding food safety and animal health (e.g., avian influenza, African swine fever) can lead to demand spikes for targeted vaccines and feed additives. - **Companion Animal Segment Growth:** While still a smaller contributor, increasing pet ownership and a premiumization trend in pet health and nutrition offers incremental upside in higher-margin areas.

⚠ Risk Factors to Monitor

PAHC faces numerous sector- and company-specific risks: - **Regulatory Changes:** The animal health industry is heavily regulated, with evolving restrictions on antibiotic use, product registrations, and safety standards varying by jurisdiction; compliance costs and risks of product bans are ongoing concerns. - **Commodity Input Price Volatility:** Raw materials used in mineral nutrition products and manufacturing processes can be subject to price swings, potentially pressuring margins. - **Customer Consolidation:** Continued consolidation among agricultural producers and distributors may shift bargaining power, leading to pricing pressures and customer concentration risk. - **Disease and Market Cyclicality:** Disease outbreaks and related shifts in animal populations can cause near-term demand unpredictability, while broader agricultural cycles impact volumes of livestock and poultry under management. - **Product Development & Competitive Risk:** Sustained innovation is necessary to defend market share as multi-national competitors (including Zoetis, Merck Animal Health, Elanco, and Boehringer Ingelheim) increase investment in animal health. - **Foreign Exchange and Geopolitical Risk:** Global operations expose the company to currency volatility, trade restrictions, and potential geopolitical tension, which can disrupt sales channels or supply chains.

📊 Valuation & Market View

Phibro is often valued in line with other animal health and agricultural input providers, focusing on earnings multiples, free cash flow generation, and potential for margin accretion. The company’s multi-segment exposure provides some resilience against cyclicality, yet margins in the mineral nutrition and performance products segments typically lag pure-play animal health leaders. Growth-focused investors may scrutinize the pace of international expansion, success of new product introductions, and the effectiveness of cost discipline initiatives relative to industry peers. Market sentiment frequently tracks expectations for global protein demand, regulatory tailwinds or headwinds, and management’s ability to drive above-industry growth in a consolidating sector. Compared to large-cap peers with higher-margin companion animal franchises, PAHC typically trades at a discount, reflecting its more utilitarian, production-focused customer base and exposure to commodity price swings.

🔍 Investment Takeaway

Phibro Animal Health represents a differentiated mid-cap play on the resiliency and incremental growth of global animal protein production and health. Its diversified business model, recurring revenue base, and proven regulatory/development capabilities position it solidly within the competitive landscape. Long-term growth is underpinned by secular trends in global protein consumption, advances in animal disease prevention, and the ongoing professionalization of livestock management—especially in emerging markets. However, investors must carefully weigh exposure to regulatory shifts, agricultural commoditization, and exposure to international volatility. While not a pure play on companion animal margin expansion, PAHC offers a stable, if more utilitarian, avenue to access global trends in animal health, nutrition, and food safety.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"PAHC reported revenue of $373.91M and a net income of $27.46M, translating to an earnings per share (EPS) of $0.68. The company reported a free cash flow deficit of $4.50M attributed to higher capital expenditures against operating cash flow of $9.30M. With total assets of $1.41B against total liabilities of $1.07B, PAHC maintains equity of $332.36M and a net debt of $717.68M. Shareholder returns remain consistent with quarterly dividends of $0.12, although higher returns were directly influenced by a significant stock price appreciation of 151.50% over the past year. This performance underlines a strong market sentiment amid a backdrop of improving profitability, despite current challenges in cash flow management. PAHC’s leverage appears moderate, and analysts have set a price target consensus at $49, aligning closely with the current market price of $55.48, suggesting a potential for price stabilization at these levels."

Revenue Growth

Good

Strong revenue growth indicating demand for products.

Profitability

Positive

Positive net income with potential for further improvement.

Cash Flow Quality

Caution

Negative free cash flow raises concerns over sustainability.

Leverage & Balance Sheet

Neutral

Moderate leverage with considerable debt relative to equity.

Shareholder Returns

Strong

High stock price appreciation and consistent dividends.

Analyst Sentiment & Valuation

Positive

Analysts view the stock positively, with targets suggesting a stable valuation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

So What: Management delivered strong Q2 momentum—consolidated sales +21% to $373.9M and adjusted EPS +58%—with Animal Health +26% sales and +41% adjusted EBITDA. The core drivers were Zoetis/combined MFA execution (integration + pricing + mix) and margin expansion, with one temporary gross margin tailwind from tier-transition returns (explicitly <100 bps). The “messy” part is in the Q&A: legacy MFA was down 5% due to a single customer’s inventory timing (~$10M), and they explicitly expect that lumpiness to normalize in the second half. Guidance was raised materially for FY26 (sales to ~$1.45–1.50B; adjusted EBITDA to ~$245–255M; adjusted net income to ~$120–127M). The analyst pressure centered on what is structural vs temporary; management leaned on pricing/mix and Phibro Forward as structural, but provided limited quantification of the margin split between structural cost initiatives and cyclical benefits—while repeatedly emphasizing confidence that any timing effects are behind them into 2H and full comparatives will drive a more “normalized” growth rate.

AI IconGrowth Catalysts

  • Medicated feed additives (MFA) led with +34% growth
  • Nutritional specialties +9% growth; vaccines +13% growth (Latin America poultry + higher international demand)
  • Improved gross margin driven by mix and pricing (especially Zoetis portfolio) and internal focus on higher-margin growth
  • Zoetis MFA outperformance tied to integration execution, share gains in anoxidil programs, and products supporting heavier harvest weights / longer feeding cycles
  • Companion animal oral health: Restore launch gained traction post-holiday season; additional vet-event momentum (VMX Orlando foot traffic)

Business Development

  • Zoetis MFA portfolio (pricing gains on Zoetis portfolio referenced explicitly)
  • Customer/portfolio timing: a single large legacy MFA customer with variable inventory levels (timing impact ~ $10M in quarter)
  • Trade shows/exposure: IPPE (Atlanta), National Beef Cattlemen’s Association (Nashville), VMX (Orlando); Restore showcased as first-time PAHC exhibitor at VMX

AI IconFinancial Highlights

  • Reported: $373.9M consolidated net sales (+21% YoY) and adjusted EBITDA +41% YoY
  • Animal health net sales: $290M (+26% YoY); Animal health adjusted EBITDA: $82.2M (+41% YoY)
  • Adjusted net income +60% YoY; adjusted diluted EPS +58% YoY
  • Legacy MFA net sales -5% in-quarter due to inventory timing at one large customer; without timing, legacy MFA growth would have been +3%
  • Inventory build negatively impacted cash generation ahead of tariffs: management stated inventory buildup reduced cash generation (amount not quantified)
  • Gross leverage: 3.1x (total debt $737M; TTM adj EBITDA $235M); Net leverage: 2.8x (net debt $662M; TTM adj EBITDA $235M)
  • Gross margin commentary (drivers): price (additional pricing on Zoetis portfolio exceeded expectations), strong mix (nutritional specialties & vaccines), and a one-time/temporary effect from tier-three to tier-one transition returns; the gross margin elevation from tier transition was 'less than ... 100 basis points'

AI IconCapital Funding

  • Free cash flow: $47M positive for twelve months ended Dec 31, 2025
  • Operating cash flow: $93M; Capex: $46M (for twelve months ended Dec 31, 2025)
  • Cash and cash equivalents + short-term investments: $74.5M at quarter end
  • Quarterly dividend: 12¢ per share ($4.9M aggregate)

AI IconStrategy & Ops

  • MFA integration progress cited as a key contributor: increased ability to leverage infrastructure without proportional additional staffing
  • Phibro Forward initiatives: management expects optimal/max contribution in FY27; contributions accelerate in 2H26 and annualization in FY27
  • Structural cost initiatives vs mix/cyclical not quantified in dollars; management emphasized structural contributions via higher gross margin and R&D/technology approach (no split disclosed)

AI IconMarket Outlook

  • Raised FY2026 guidance (vs prior):
  • Net sales: increased to $1.450B–$1.500B (from $1.425B–$1.475B), implying +12% to +16% growth; midpoint ~14%
  • Total adjusted EBITDA: $245M–$255M (from $230M–$240M), implying +33% to +39% growth; midpoint ~36%
  • Adjusted net income: $120M–$127M (from $108M–$115M), implying +41% to +49% growth; midpoint ~45%
  • GAAP net income/EPS guidance assumes constant currency and no additional FX gains/losses; includes one-time costs related to Phibro Forward income growth initiatives
  • Companion animal oral health/oral health contribution expected limited in Q2; slightly more in 2H26; more material in FY27

AI IconRisks & Headwinds

  • Inventory buildup ahead of tariffs: management said cash generation was negatively impacted; expects inventory stabilization in coming quarters
  • Legacy MFA lumpiness risk: timing fluctuations from one large customer’s inventory levels; in Q2 impact roughly $10M negative to legacy MFA
  • Comparability/normalization: legacy and Zoetis MFA growth expected to slow in 2H due to moving from partial quarter comparisons to full comparatives; long-term legacy MFA growth expected low-to-mid single digits
  • Macro/cycle: management acknowledged possible shifts in trade between countries driven by tariffs and/or disease outbreaks (no specific mitigation beyond inventory stabilization/expectations around operating momentum)

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PAHC Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PAHC)

© 2026 Stock Market Info — Phibro Animal Health Corporation (PAHC) Financial Profile